Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO)

CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

CERo Therapeutics Holdings, Inc. logo

CERo Therapeutics Holdings, Inc.

OTC:CEROHealthcare
-4.17%$0.0046
Mkt Cap$383K
EV-
Float–
O/S83.31M
VOL105K sh
$ Vol$463
RVOL0.28×
Inst Own-
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution

CERO THERAPEUTICS HOLDINGS, INC. (CERO) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 39 SEC filings.

Shelf registration
S-3 filed Aug 11, 2025, effective Aug 15, 2025
Source: 10-Q filed Nov 13, 2026
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
8 warrant series recorded as outstanding
Most recent offering
PIPE, closed Aug 11, 2026
Source: 10-Q filed Nov 13, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro